摘要
【摘要】 目的：探讨曲美他嗪联合比索洛尔治疗风湿性心脏病慢性心力衰竭患者的临床研究。方法：选取 2018 年 6 月至 2019 年 6 月在我院内科收治的 86 例患者作为研究对象。通过随机分组法，将其分为对照组与观察组各 43 例。对照组患者给予常规方案 + 比索洛尔治疗，观察组在对照组基础上联合曲美他嗪治疗。通过比较两组患者的临床疗效、治疗前后心功能指标以及 6min 步行距离情况。结果：①两组疗效对比，观察组总有效率显著高于对照组（ 90.7%vs74.4% ），具有统计学差异性（ P<0.05 ）；②治疗后，观察组患者的心功能指标 LVESD 、 LVEED 、 LAEF 值及 6min 步行距离均优于对照组，具有统计学差异性（ P<0.01 ）。结论：风湿性心脏病慢性心力衰竭患者，应用曲美他嗪联合比索洛尔治疗，能显著改善患者心功能，提高活动耐力，疗效确切，值得推广应用。
【关键词】曲美他嗪； 比索洛尔； 风湿性心脏病； 心力衰竭
[Abstract] Objective: To explore the clinical study of trimetazidine combined with bisoprolol in the treatment of rheumatic heart disease and chronic heart failure. Methods: 86 patients admitted to our hospital from June 2018 to June 2019 were selected as research objects. The patients were randomly divided into control group and observation group with 43 cases each. The patients in the control group were treated with routine regimen and bisoprolol, while the patients in the observation group were treated with trimetazidine on the basis of the control group. The clinical effect, cardiac function index before and after treatment and 6-minute walking distance of the two groups were compared. Results: ① the total effective rate of the observation group was significantly higher than that of the control group (90.7% vs 74.4%), with statistical difference (P < 0.05); ② after treatment, the values of LVESD, lved, laef and 6-min walking distance of the observation group were better than those of the control group, with statistical difference (P < 0.01). Conclusion: trimetazidine combined with bisoprolol can significantly improve the heart function and activity tolerance of patients with rheumatic heart disease and chronic heart failure, which is worth popularizing.
出版日期
2020年04月28日（中国期刊网平台首次上网日期，不代表论文的发表时间）
